Linperlisib plus rituximab for relapsed low-grade lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two drugs, linperlisib (a PI3K inhibitor) and rituximab, for people whose indolent (slow-growing) non-Hodgkin lymphoma has come back or stopped responding to treatment. It aims to see if adding linperlisib to rituximab can help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have received at least 1 previous treatment for your lymphoma.
- You have been treated with rituximab or a similar drug before.
- You have a tumor that can be measured (at least 1.5 cm in a lymph node or 1 cm elsewhere).
- Your liver, kidneys, and blood cell counts are working adequately.
- You have not taken a PI3K inhibitor before.
- You do not have active hepatitis B, C, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs (linperlisib, cyclophosphamide, prednisone, and thalidomide) for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments. It aims to see if this combination can help control the disease.
This trial tests a drug called linperlisib combined with standard chemotherapy and immunotherapy for people with large B-cell lymphoma that has come back or not responded to one prior treatment.
This trial tests a new drug called Linperlisib for people with a rare type of leukemia (T-cell large granular lymphocytic leukemia) that has come back or stopped responding to previous treatment. It's a possible option for patients whose blood counts are low, who have an enlarged spleen, or who have other related health problems.
This trial tests whether adding the targeted drug linperlisib to standard chemotherapy (CHOP) can help adults with certain types of peripheral T-cell lymphoma that haven't been treated yet. It aims to see if the combination works better than CHOP alone.
This trial is testing a combination of two targeted drugs (linperlisib and an EZH2 inhibitor) for people whose peripheral T-cell lymphoma has come back or not responded to previous treatment. The goal is to see if this new combination can help shrink tumors and slow the disease.
This trial tests a combination of two oral drugs, chidamide and linperlisib, for people with follicular lymphoma that has not responded to or come back after at least two prior treatments. The goal is to see if this combination can help shrink the lymphoma and stop it from growing.
Hear when a new Relapsed/Refractory Indolent NHL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.